Pages that link to "Q30689293"
Jump to navigation
Jump to search
The following pages link to The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry (Q30689293):
Displaying 50 items.
- Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C (Q28552691) (← links)
- The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma (Q30250096) (← links)
- A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound (Q33918841) (← links)
- Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C (Q35031753) (← links)
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study (Q35538245) (← links)
- Detergent-resistant membrane association of NS2 and E2 during hepatitis C virus replication (Q35641053) (← links)
- Impact of hepatitis C virus eradication on hepatocellular carcinogenesis (Q35985401) (← links)
- Predictors for Early Identification of Hepatitis C Virus Infection (Q36043559) (← links)
- Hepatitis C virus infection: Are there still specific problems with genotype 3? (Q36269670) (← links)
- Clinical Liver Disease Progression Among Hepatitis C-Infected Drug Users With CD4 Cell Count Less Than 200 Cells/mm(3) Is More Pronounced Among Women Than Men. (Q36650557) (← links)
- Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C. (Q36716281) (← links)
- Is exposure to Agent Orange a risk factor for hepatocellular cancer?-A single-center retrospective study in the U.S. veteran population (Q36937018) (← links)
- Distribution of Hepatitis C Risk Factors and HCV Treatment Outcomes among Central Canadian Aboriginal (Q36997013) (← links)
- Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens (Q37116816) (← links)
- The clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study (Q37226231) (← links)
- Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population (Q37484155) (← links)
- Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders (Q37641036) (← links)
- Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis (Q38207083) (← links)
- Hepatitis C virus genotype 3: a genotype that is not 'easy-to-treat'. (Q38249236) (← links)
- Cure of HCV related liver disease (Q38295834) (← links)
- Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. (Q38341993) (← links)
- Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. (Q38522791) (← links)
- Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions (Q38728564) (← links)
- Engagement in Care of High-Risk Hepatitis C Patients with Interferon-Free Direct-Acting Antiviral Therapies (Q38854076) (← links)
- Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. (Q38972499) (← links)
- Clinical characteristics, healthcare costs, and resource utilization in hepatitis C vary by genotype (Q38995692) (← links)
- The impact of antiviral therapy for hepatitis C on the quality of life: a perspective (Q39067380) (← links)
- Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV. (Q40271866) (← links)
- Identification of novel variants in HLA class II region related to HLA DPB1 expression and disease progression in patients with chronic hepatitis C. (Q40279001) (← links)
- Racial diversity in mortality and morbidity in urban patients with hepatitis C. (Q40348098) (← links)
- Building the evidence base to eliminate hepatitis B and C as public health threats (Q40586834) (← links)
- Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients (Q40989818) (← links)
- Effect of Treatment for CHC on Liver Disease Progression and Hepatocellular Carcinoma Development in African Americans (Q41084425) (← links)
- Contextual analysis of determinants of late diagnosis of hepatitis C virus infection in medicare patients (Q41261310) (← links)
- Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis (Q41610405) (← links)
- HCV genotype 3: a wolf in sheep's clothing. (Q42985723) (← links)
- Hepatitis C Treatment at a Veterans Affairs Medical Center After the Availability of Direct-Acting Agents: Things Are Looking Up. (Q45328050) (← links)
- Need of informatics in designing interoperable clinical registries. (Q48633948) (← links)
- Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis? (Q50104271) (← links)
- Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. (Q53837635) (← links)
- Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort. (Q54269145) (← links)
- Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C (Q57071808) (← links)
- Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges (Q57162382) (← links)
- Challenge of hepatitis C in Egypt and hepatitis B in Mauritania (Q57491236) (← links)
- Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank (Q58564271) (← links)
- Sofosbuvir in combination with ribavirin or simeprevir: real-life study of patients with hepatitis C genotype 4 (Q60948410) (← links)
- Short-term budget affordability of hepatitis C treatments for state Medicaid programs (Q64086154) (← links)
- High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting. (Q64898430) (← links)
- What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection? (Q91656302) (← links)
- Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals (Q92488291) (← links)